1.Alternative Name:CLL-1
2.Target:CLEC12A
3.Source:Human CLEC12A was expressed from HEK293 with poly His at the N-terminal
4.Sequence:His65-Ala265
5.Protein structure:HisQ5QGZ9
6.Molecular Characterization:The protein has a calculated MW of 28kDa.The reducing (R) heterodimer protein migrates as 35-60 kDa due to glycosylation
7.Purity:SDS-PAGE>90%，SEC>95%
8.Reconstitution:sterile H2O
9.Endotoxin:<1EU/mg
10.Formulation:Lyophilized from 0.22 μm filtered solution in PBS, pH7.4.
11.SDS-PAGE

Determined by SDS-PAGE, the purity of the protein is greater than 90%.

12.SEC-HPLC

Determined by SEC-HPLC, the purity of the protein is greater than 95%.

13.ELISA

When Recombinant Human CLEC12A（CLL-1）/His Protein is immobilized at 2μg/mL (100 μL/well), the concentration of Anti-Human CD3E/CLEC12A(tepoditamab) that produces 50% of the optimal binding response is approximately 0.8ug/ml.

Note：For research use only .